References


11. Harrison CN, Schapp N, Vannuchi AM, et al. Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in
Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. ASH 2019. Abstract 2207.


